Abstract 2137P
Background
Performance ECOG status and staging are described as prognostic factors in oncologic outpatients while nutritional assessment can impact survival in both outpatients and inpatients. The aim of this study was to describe the Charslon Comorbidity Index (CCI), the nutritional status, the impact of opioid therapy and psycho-oncology and palliative care unit intervention for hospitalized cancer patients (pts).
Methods
A prospective multicentric study of pts hospitalized between January 2020 February 2022 at Vall d’Hebron and Sant Pau Hospitals [Plantology database] in Spain. Demographic and clinical variables such as CCI, laboratory results and nutritional status were collected at admission. Prognostic Nutritional Index (PNI) was calculated at admission. Quality of life (QoL) was collected through the EORTC-QLQ30 v.3 questionnaire. Statistical analysis was performed with SPSS v.29 (Log rank, Chi-square, Student’s t-test were used).
Results
A total of 1.431 patients (median age 66 years, 53.2% males) were included with a median of 9 days hospitalized. With a follow-up of 15 months, the median survival was 4.67 months after admission. Most pts (91.6%) had severe comorbidity (CCI ≥ 5 points) related to a lower survival (4.5 vs 12.8 months, p<0.001). A positive chair stand test for sarcopenia (12.2%) was associated with reduced survival (3.5 vs 9.1 months, p<0.001). Pts with hypoalbuminemia (65.3%) presented lower survival (3.5 vs 8.4 months, p<0.001). In addition, the PNI stratified 59.5% pts with serious malnutrition (PNI <40) linked to reduced survival (3.6 vs 7.9 months, p<0.001). Regarding supportive care, pts under opioid therapy (39.6%) had a higher QoL (mean EORTC QLQ-30 score of 73.4 vs 64.3, p<0.001). Palliative care team assessment and psycho-oncology intervention positively impacted in pts QoL (EORTC QLQ-30 of 74 vs 67.3, p<0.001, and 74.3 vs 65.2, p<0.001, respectively).
Conclusions
In hospitalized cancer pts, severe comorbidity, malnutrition and sarcopenia were associated with a reduced survival. Opioid therapy and psycho-oncological and palliative care unit intervention had a positive impact on the QoL of pts. Early supportive care interventions are key to improve symptomatology and preserve QoL of hospitalized cancer pts.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
VHIO.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2151P - Incidence patterns and clinical implications of venous thromboembolism (VTE) in patients (pts) with neuroendocrine tumors (NET)
Presenter: Jorge Hernando
Session: Poster session 07
2152P - Prognostic importance of GRIM score on sorafenib side effects, hospitalization and survival in hepatocellular cancer patients
Presenter: Duygu Ercan Uzundal
Session: Poster session 07
2153P - Circulating biomarkers to predict severe complications in cancer patients with low-risk chemotherapy-associated febrile neutropenia
Presenter: Sofía Wikström Fernandez
Session: Poster session 07
2154P - Total cholesterol as an independent prognostic factor in cancer patient survival: A single institution experience
Presenter: Maria Alameda-Guijarro
Session: Poster session 07
2156P - Use of taxanes during pregnancy: A systematic review
Presenter: Ana Ferrigno Guajardo
Session: Poster session 07
2157P - A phase II randomised controlled trial comparing the cardiotoxicity of capecitabine and S-1
Presenter: Sally Clive
Session: Poster session 07
2158P - A self-assessment survey to identify the risk of patient’s screen fail in phase I clinical trials (SCITEP trial)
Presenter: Kaissa Ouali
Session: Poster session 07
2159P - Machine learning algorithms to predict the risk of chemotherapy-related toxicity in older Asians
Presenter: Mingwei Li
Session: Poster session 07
2160P - Sociodemographic disparities associated with financial toxicity in stage IV non-small cell lung cancer survivors
Presenter: Mitchell Parma
Session: Poster session 07
2161P - Organization of hospital pharmaceutical consultations for cancer patients receiving oral anticancer drugs: A nationwide cross-sectional study
Presenter: Florian Slimano
Session: Poster session 07